Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$8.93
+1.3%
$9.21
$6.38
$17.30
$863.41M1.421.23 million shs361,574 shs
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
$0.01
$0.01
$0.02
$1.19M-1.01435,993 shs39,482 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.26
-0.8%
$1.40
$1.12
$2.55
$61.80M0.436,314 shs68,347 shs
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
$1.10
$1.08
$0.59
$8.08
$36.47M0.1701,788 shsN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$0.23
$0.06
$1.35
$1.87M2.183.66 million shs29.90 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
+1.31%-3.93%-5.36%+31.25%-38.58%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00%+5.26%+5.26%+3.09%+4.71%
MediciNova, Inc. stock logo
MNOV
MediciNova
-0.79%-3.08%-10.64%+1.61%-10.00%
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
0.00%0.00%0.00%0.00%-91.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
2.4457 of 5 stars
3.53.00.00.01.01.70.6
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.8601 of 5 stars
0.03.00.04.80.00.00.0
MediciNova, Inc. stock logo
MNOV
MediciNova
1.8893 of 5 stars
3.82.00.00.00.00.80.0
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
3.00
Buy$18.17103.55% Upside
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.00
N/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
3.50
Strong Buy$7.00455.56% Upside
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
0.00
N/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AVDL, MNOV, EVFM, STSA, and VBIV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.00
5/8/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
4/9/2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
4/9/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$169.12M5.11N/AN/A$0.77 per share11.59
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$11.39M0.10N/AN/A($2.64) per share0.00
MediciNova, Inc. stock logo
MNOV
MediciNova
$1M61.80N/AN/A$1.07 per share1.18
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/A$1.41 per shareN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
$9.41M0.00N/AN/A$0.32 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-$48.83M-$0.27N/A148.75N/A-13.58%-36.07%-16.30%8/6/2025 (Estimated)
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$0.05N/AN/A-46.42%-91.97%-61.93%N/A
MediciNova, Inc. stock logo
MNOV
MediciNova
-$11.04M-$0.23N/AN/AN/AN/A-20.77%-19.68%8/6/2025 (Estimated)
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
-$70.06M-$2.01N/AN/AN/AN/A-115.24%-102.26%N/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
-$92.84MN/A0.00N/AN/A-881.79%-525.42%-45.87%N/A

Latest AVDL, MNOV, EVFM, STSA, and VBIV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.14-$0.06+$0.08-$0.06N/AN/A
5/7/2025Q1 2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/AN/A
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/A
2.73
2.33
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.11
0.09
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
17.66
17.66
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/A
7.44
7.44
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
N/A
0.34
0.21

Institutional Ownership

CompanyInstitutional Ownership
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
69.19%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.22%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
93.26%
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
12.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
7096.74 million91.71 millionOptionable
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
120118.66 million113.12 millionNot Optionable
MediciNova, Inc. stock logo
MNOV
MediciNova
1049.05 million42.38 millionOptionable
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
2133.15 million22.81 millionNot Optionable
VBI Vaccines Inc. stock logo
VBIV
VBI Vaccines
2228.68 million25.71 millionOptionable

Recent News About These Companies

VBI recalls PreHevbrio and winds down operations
Why Is VBI Vaccines (VBIV) Stock Up 62% Today?
VBI craters as investors react to Hep B vaccine data
VBI Vaccines Reports Full Year 2023 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avadel Pharmaceuticals stock logo

Avadel Pharmaceuticals NASDAQ:AVDL

$8.93 +0.12 (+1.31%)
As of 07/3/2025 02:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Evofem Biosciences stock logo

Evofem Biosciences NASDAQ:EVFM

$0.01 0.00 (0.00%)
As of 07/3/2025 11:39 AM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.26 -0.01 (-0.79%)
As of 07/3/2025 01:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Satsuma Pharmaceuticals stock logo

Satsuma Pharmaceuticals NASDAQ:STSA

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

VBI Vaccines stock logo

VBI Vaccines NASDAQ:VBIV

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.